Inimmune, a leading biotech company focused on the development of novel immunotherapies and vaccine adjuvants announced the publication of pre-clinical efficacy and safety data for INI-2004. „Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization“ was published in Frontiers in Immunology on July 23, 2024 (https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1421758/full). This research highlights the significant disease modifying impacts of INI-2004 in allergic disease following intranasal administration and describes the remarkable safety profile of this innovative treatment.
